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Abstract
Mesenchymal stromal cells (MSCs) have the capacity for self-renewal and multi-lineage dif-
ferentiation, have many advantages over other cells, and are thought to be one of the most 
promising cell sources for cell-based treatments. In fact, MSCs have already been widely 
applied in clinics as a treatment for numerous disorders, including orthopedic diseases, 
such as bone fracture, articular cartilage injury, osteoarthritis (OA), femoral head necrosis, 
degenerative disc, meniscus injury, osteogenesis imperfecta (OI), and other systemic bone 
diseases. With the progressions in R&D, the safety and efficacy of MSC-based treatments 
in orthopedic diseases have been largely recognized, but many challenges still exist. In 
this chapter, we intend to briefly update the recent progressions and discuss the potential 
issues in the target areas. Hopefully, our discussion would be helpful not only for the clini-
cians and the researchers in the specific disciplines but also for the general audiences.
Keywords: mesenchymal stromal cells (MSCs), orthopedic disease, cell therapy,  
tissue engineering, regenerative medicine
1. Introduction
Around 1960s, Friedenstein first found that there was a non-hematopoietic stem cell popula-
tion in the bone marrow that could be differentiated into bone and fibrous tissue [1]; however, 
this population did not gain broad recognition until Caplan coined the term bone mesenchy-
mal stem cells (MSCs) in 1991 [2]. This umbrella term did raise up the attention of this popula-
tion, but this term is misleading and very controversial, and many investigators argue against 
to use this term loosely. As a result, many different terms have been proposed for this or the 
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similar populations, including mesenchymal stromal cells (MSCs), mesenchymal progenitor 
cells, multipotent mesenchymal stromal cells, bone marrow stromal cells (BMSCs), bone mar-
row-derived MSCs, multipotent stromal cells, mesenchymal precursor cells, and skeletal stem 
cells [3]. Currently, most investigators prefer an alternative term, that is, multipotent mesen-
chymal stromal cells (MSCs). For this reason, we also use this term throughout this chapter.
Theoretically, self-renewal without significant loss of their characteristics (stemness) and 
multi-lineage differentiation potential are the two criteria that define MSCs as real stem cells, 
but in practice, this heterogeneous population proliferates in vitro as plastic-adherent cells,  as 
fibroblast-like morphology, forms colonies in vitro and can at least differentiate into bone, 
cartilage and fat cells [4]. In addition, literatures also provided evidence that MSCs can differ-
entiate into multiple other mesenchymal lineages or even non-mesenchymal cell types, includ-
ing endothelial cells, osteoblasts, chondrocytes, fibroblasts, tenocytes, vascular smooth muscle 
cells, myoblasts, and neurons [5], though some of these capacities are controversial. The key 
caveat is that it is unlikely that all cells in the cultural meet the above-mentioned two criteria.
MSC-like cells can be obtained from almost all tissues, including the umbilical cord, amniotic 
fluid, placenta, adipose tissue, joint synovium, synovial fluid, dental pulp, endosteum, and 
periosteum [6]. Cultured MSCs have been characterized either by using cell surface anti-
gens and/or by examining the cells’ differentiation potential. The International Society for 
Cellular Therapy  recommended that cells should fulfill the following criteria to be consid-
ered as MSCs: (1) the cells must be plastic adherent when maintained under standard culture 
conditions; (2) they must express CD73, CD90, and CD105 markers and should not express 
CD34, CD45, CD14, HLA-DR, CD11b, or CD19; and (3) they should be able to differentiate 
at least into osteoblasts, chondroblasts, and adipocytes in vitro [7]; however, this criteria has 
obvious problems therefore not been commonly accepted. For this reason, it is still challeng-
ing to consistently isolate or purify a well-defined clinical applicable MSC population.
On the other hand, the increasingly aging population has made the degenerative, non-trau-
matic and traumatic musculoskeletal diseases main socioeconomic issues, and MSCs seem 
to be a promising solution. In fact, MSCs have been widely used as a treatment for numer-
ous orthopedic diseases, including bone defects, osteoarthritis (OA), femoral head necrosis, 
degenerative disc, spinal cord injury, knee varus, osteogenesis imperfecta, and other systemic 
bone diseases [8]. Currently, orthopedic researchers are still focusing on overcoming a variety 
of challenges so that they can fully realize the clinical therapeutic potential of MSCs, and the 
long-term goal is to change the main treatment strategy in the field of orthopedics from surgi-
cal replacement and reconstruction to bioregeneration and prevention [9].
In this chapter, we will briefly update the main advancements in these areas and discuss the 
major current and potential future applications pathways.
2. MSCs in nonunion bone fracture
Inadequate healing can lead to nonunion of the fractured bone. Clinically, about 5–10% of 
all fractures end up in persistent nonunion [10]; therefore, nonunion is one of the most trou-
blesome complications. Since MSCs have the osteogenic differentiation ability, can secrete a 
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variety of cytokines and promote angiogenesis. It is reasonable to speculate that MSCs could 
accelerate fracture healing. In fact, there are experimental evidences to support the idea that 
MSCs treatment indeed promoted healing of nonunion fractures. For example, MSCs has 
been transplanted to animals to promote bone loss and fracture healing [11, 12]. Also, there 
are reports of BMSC treatment of bone nonunion caused by a bone defect, osteogenesis and 
local microenvironment disorders in patients [13–15]. It was reported that, after traumatic 
injuries, BMSCs could migrate from blood circulation to the lesion site, and then directly 
differentiate locally, and replace the injured cells. Consistently, the circulating BMSC can be 
detected in peripheral blood 39 to 101 hrs after fracture [16]. However, other data also sug-
gested that these circulating cells account for only a small portion of cells in the fracture callus 
under normal circumstances, suggesting that the majority of the cells at the fracture site are 
migrated from the adjacent tissues [13]; nevertheless, therapeutic amplification of circulating 
MSCs through their mobilization could also represent a potential therapeutic opportunity in 
fracture repair [13].
Indirectly, BMSCs promote bone healing mainly through the secretion of bioactive molecules 
and extracellular membrane vesicles, which induce angiogenesis, regulate inflammation, 
inhibit apoptosis, and regulate osteogenesis differentiation. Since defective blood supply 
(ischemia) is an important cause of nonunion of bone, promoting blood vessel formation is 
beneficial to the healing of the nonunion bone. MSCs are known to secrete angiogenesis-
related factors include angiopoietin Ang-1 and Ang-2, vascular endothelial growth factor 
(VEGF), FGF-2, and hepatocyte growth factor (HGF)-1 [17]. Furthermore, BMSCs have an 
anti-fibrotic effect and can limit that fibrosis progression of fracture zone and promote the 
regeneration of bone tissue. This is mainly accomplished by immunoregulating, inhibiting 
TGF-3 mediated differentiation of fibroblasts, inhibiting oxidative stress, and matrix recon-
struction [18]. Interestingly, it was also found that HGF, VEGF, and microbubble secreted 
by BMSCs had an anti-apoptotic effect, which inhibits the apoptosis of transplant cells in the 
injured area [19, 20].
In addition, other conserved signaling pathways, such as the transformation growth factor 
(TGF)-β
3
/bone morphogenetic proteins (BMP), Wnt, Hedgehogs, FGF, platelet-derived factor 
(PDGF), epidermal cell growth factor (EGF), and insulin-like growth factor (IGF), may also 
indirectly participate in the regulation of BMSCs and promote bone healing processes [21, 22]. 
Based on these observations, factors such as TGF-β
3
 and its analogs, BMP, BMP-2, and BMP-7, 
have been used clinically to enhance and accelerate the bone repair or regeneration.
Technically, MSCs can be isolated from many different tissues. The iliac crest is the ideal posi-
tion for bone marrow aspiration. In clinical practice, we indeed found that injection of bone 
marrow aspirate into the fracture space can promote the healing of fracture and shorten the 
healing time. For example, in one case with an open tibial fracture, which did not develop cal-
lus within the 6 months after surgery, and then we extracted marrow aspirate from the iliac 
crest and injected it into the fracture space. We found that the fracture healed well 6 months 
after the transplantation (Figure 1). Consistently, bone marrow aspirate injection has been 
shown to have a potential role in the treatment of aseptic, atrophic nonunions with accept-
able alignment and minimal gap, or displacement between fracture fragments [15]. Generally, 
Tibial nonunion treatment with bone marrow aspirate has been well-documented and found 
to be successful in 75–90% of reported tibial nonunion case series [23, 24].
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Figure 1. (A) A 32-year-old male underwent external fixation of an open tibial fracture. After surgery, no callus was observed in 6 months. (B, C) he underwent bone 
marrow aspiration and percutaneous grafting directly into the nonunion site. (D, E) 6 months after the transplantation, frontal and lateral X-ray images indicated the 
fracture healed well.
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Researchers have described the purification and expansion of bone marrow MSCs from mice, 
rats, rabbits, dogs, and humans, and the ability of these cell populations to form bone when 
implanted ectopically with hydroxyapatite or an appropriate carrier has been established. 
To isolate MSCs from blood, mobilization of MSCs to the peripheral circulation with granu-
locyte colony-stimulating factor (G-CSF) is normally necessary. Data also suggests that the 
tissue-engineered constructs with MSCs (either genetic modified or not) brings us closer to 
a clinical application. However, nonunion still occurred in nearly half of the bone defects 
in a large animal model [25]. In fact, the commonly accepted idea that atrophic nonunion is 
due to lack of MSCs activities of MSCs might be not accurate. For example, an interesting 
study found the existence of MSCs (confirmed by their expression profile of CD105, CD73, 
HLA-DR, CD34, CD45, CD14, and CD19) in the site of atrophic nonunion, at a similar num-
ber and viability to those isolated from the iliac crest [26]. In another clinical study, Ismail 
et al. [14] also reported that iliac crest autograft with or without autologous MSCs (with 5 g/
cm3 hydroxyapatite granules, as scaffold carrier) had similar treatment efforts on atrophic 
nonunion.
3. MSCs in articular cartilage injury
Due to the limited ability of proliferation capacity of chondrocytes, articular cartilage 
injury often causes progressive degeneration of the joint and OA, which is a serious 
health and economic problem [27]. The typical current treatment for this disorder is 
microfracture, which is a surgical technique that was developed 20 years ago. This treat-
ment uses the body’s own healing abilities to regenerate the chondral surface. However, 
the regenerated fibrocartilage often has poor mechanical properties compared with nor-
mal cartilage.
Recently, the MSC-based autogenous transplantation treatment was proposed, since the 
potential of the MSCs to differentiate into chondrocytes has been well-recognized [28]. 
Compared with allogeneic cells, generally, autogenous cartilage progenitor cells are more 
effective in the treatment of articular cartilage defect [29]. The emerging typical paradigm to 
apply MSCs in this disorder is [30]: (1) during the first operation, a cartilage biopsy is taken 
from areas of damaged cartilage within the ankle or knee; (2) chondrocytes are isolated from 
the biopsy via enzymatic digestion and cultured in 2D monolayer cultures; (3) monolayer 
culture-expanded chondrocytes are seeded on a collagen type I–III membrane; and (4) in the 
second operation, the cartilage lesion is prepared and the collagen membrane is cut to size, 
placed in the lesion and secured with fibrin glue.
To clarify whether donor MSCs indeed contribute to cartilage regeneration in vivo via a 
progenitor-mediated mechanism [31], Zwolanek et al. describe a novel cell tracking system 
based on genetic transgenic donor and corresponding cell marker, and the results showed 
that MSC could contribute to cartilage regeneration via a progenitor - or nonprogenitor - 
mediated mechanism [31]. The study by Windt et al. in humans also produced similar results 
[32]. Further study found that chondrogenesis can be regulated by adjusting the time and 
concentration of TGF-β [33].
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To further improve the efficiency of MSC-based treatment, combining bone marrow-derived 
MSCs with scaffold have been tried for the reconstruction of cartilage [34]. For example, 
Sadlik et al. reported that the scaffold-embedded MSC was implanted into the knee to repair 
cartilage through dry arthroscopy, and the tissue regeneration was successful [27]. In addi-
tion, other approaches, such as the stem cells cultured from the subpatellar fat pad of arthritis 
patients can also be induced to differentiate into chondrocytes, which are very similar to the 
normal chondrocytes [29]. Koga et al. also found that the transplantation of synovial MSCs 
(SMSCs) in a rabbit model resulted in a large number of cartilage matrix development, and 
they also observed that SMSCs differentiated into osteocytes deeper into the defect, but dif-
ferentiated into chondrocytes on the surface [35].
4. MSCs in meniscus injury
Meniscus injury in the knee joint is probably the most frequent intra-articular damage. The 
typical treatment is a partial surgectomy, but it can lead to degeneration of articular carti-
lage, narrow joints, and early osteoarthritis. Intra-articular injection of MSCs could be a sim-
ple treatment with little damage since MSCs might promote the regeneration of meniscus. 
Indeed, it was found that when MSCs were injected directly into the articular cavity, they 
could migrate to the lesion site, directly participate in the tissue repair, and induce the repair 
of the host through the collateral secretion, and replace the injured tissue [36]. Murhpy et al. 
reported the first study of injection of BMSCs in sheep articular cavity [37], and observed 
the obvious repair of cartilage damage in meniscus injury, 6 and 12 weeks after injection. 
Whitehouse et al. also reported that undifferentiated MSCs/collagen-scaffold implant could 
provide a safe way to augment avascular meniscal repair in some patients [38]. Another study 
investigating the injection of allogenic MSCs in the context of post-subtotal meniscectomy 
found that there was evidence of meniscal regeneration in the two groups treated with MSCs 
[39]. However, Hong et al. used arthroscopic surgery to repair the meniscus of the posterior 
articular cavity with or without BMSCs after meniscus injury [40], and found that the menis-
cus and tibial plateau were not fully integrated, and the efficacy of MSCs treatment group 
was not significantly different from that of the control group. They argued that MSCs may 
differentiate into other tissue cells if they were not effectively induced to differentiate into 
specific cell types. Therefore, it is still a challenge to induce the cells into the meniscus carti-
lage phenotype in this context.
5. MSCs in the treatment of osteoarthritis
Osteoarthritis (OA) is a major cause of joint pain and loss of mobility in the elderly, which 
seriously affects the quality of life and causes huge social and economic burden. Many 
researchers have conducted a series of clinical studies on BMSCs transplantation to treat OA 
(Table 1), and these studies demonstrated that moderate confidence could be placed on the 
safety of MSCs therapy for knee OA, but the confidence in efficacy outcomes is low, mainly 
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due to limited clinical case number [46]. Therefore, further high-quality studies for OA with 
high internal and external validity are still required. In addition, Shi et al. compared the clini-
cal results of platelet-rich plasma (PRP) and MSCs treatments for osteoarthritis of the knee 
in a systematic review and pointed out MSCS provide more significant disease therapeutic 
effect [47].
6. MSCs in femoral head necrosis
Avascular necrosis of the femoral head (ANFH) is a serious clinical problem. If untreated, about 
80% of ANFH progresses to the collapse of the head within 1–4 years [48]. Numerous clinical 
methods have been tried, including core decompression (CD), a commonly used method for 
treating the early stages of ANFH. The presumption is that CD can reduce the intraosseous 
pressure and also stimulate stem cell regeneration. But the outcome of CD is variable and is 
still controversial.
With the development of non-biological materials, MSCs and tissue engineering techniques, 
the treatment of ANFH has been significantly improved recently [49]. For example, it was 
References Location BMCSa Follow-up 
time
No. 
of 
cases
Pain subscale Outcomes
Pre-infusion values Post-infusion 
values
[41] knee Auto_
BM_MSC
1 year 12 24 ± 14b 6 ± 6b pain 
improvement, 
higher cartilage 
quality (MRI)
[42] knee Auto_
AT_MSC
6 months 12 56 ± 19b 34 ± 23b clinical 
improvements
[43] knee Allo_
BM_MSC
1 year 15 46 ± 15b 30 ± 16b pain 
improvement, 
higher cartilage 
quality (MRI)
[44] knee Auto_
BM_MSC
24 weeks 2 4c 0.38c pain 
improvement, 
higher cartilage 
quality (MRI)
[45] Hip Auto_
BM_MSC
3 years 10 34.5 ± 8.2b 19.2 ± 6.1b pain 
improvement, 
improved 
function
aAuto_BM_MSC, Autologous Bone Marrow-derived MSCs. Auto_AT_MSC, Autologous Adipose Tissue-derived MSC. 
Allogeneic Bone Marrow-derived MSC.
bThe WOMAC index (pain subscale) has been used; scale 0–100.
cThe VAS index (pain subscale) has been used; scale 0–10.
Table 1. Summary of MSCs as the treatment of osteoarthritis.
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reported that the efficacy of MSCs transplantation group was significantly better than that of 
the pure medullary decompression group [50]. In another study, 100 patients with early-stage 
ANFH were recruited and randomly assigned to BMMSC treatment or CD treatment only 
[51], a similar result was observed, that is, this intervention was proved to be safe and more 
effective in delaying or avoiding FH collapse. In another study of eight patients with bilateral 
femoral head necrosis, the researchers performed the medullary decompression on one side, 
while on the other side medullary decompression MSCs transplantation. The Harris hip score 
(HHS) and VAS score of the MSCs transplantation group were significantly improved, and 
the results of MRI quantitative analysis showed a significant decrease in necrosis area [52]. 
Consistently, another study found that the group of MSCs had a significantly superior recov-
ery of the early stages of necrosis [53].
However, there have been reports of unsatisfactory success rates for end-stage osteone-
crosis of the femoral head (ONFH), even with MSCs [54]. To improve the outcome, Zhao 
et al. describe a modified technique using BMSCs associated with porous tantalum rod 
implantation combined with vascularized iliac grafting for the treatment of end-stage 
ONFH, and they followed up for 5 years, and these authors found that Harris hip score 
was improved from 38.74 ± 5.88 points (range 22–50) to 77.23 ± 14.75 points (range 33–95) 
[55]. It is worthy to mention that, in this procedure, approximately 10 mL of bone marrow 
from the subtrochanteric region was directly aspirated once the decompression tunnel 
was established during the surgery, avoiding the need for bone marrow aspiration from 
the iliac crest.
7. MSCs in intervertebral disc degeneration
Intervertebral disc degenerative is a serious worldwide problem for the aging population. The 
apoptosis of nucleus pulposus cells could be the main cause of intervertebral disc degenera-
tion, with a variety of manifestations, that is, reduced number of the cells, the changes of the 
mechanical structure, down-regulated synthesis of matrix components (such as proteogly-
can), nucleus pulposus dehydration, and increased metabolic waste [56, 57]. Many treatment 
options have been proposed, including physical therapy, pain medication, epidural steroid 
drug injection, disc radiating, myeloid nucleation, intervertebral fusion, and intervertebral 
disc displacement. However, these therapeutic approaches aim only to relieve the symptoms 
of disc degeneration, not treat its underlying cause. MSCs transplantation provides a new 
therapeutic strategy for promoting proteoglycan synthesis, decelerating the course of disc 
degeneration, and stimulating disc regeneration.
For example, Sobajima et al. reported that BMSCs was injected into the lumbar interver-
tebral disc of the New Zealand white rabbit, and found that the transplanted BMSCs sur-
vived and migrated to the fibrous ring after 24 weeks [58]. Hee et al. confirmed that BMSCs 
implantation and axial distraction may have a synergistic effect in reversing degenerative 
disc disease in the rabbit model [59]. Some scholars have discovered that drug stimula-
tion can regulate the differentiation of nucleus pulposus MSCs into nucleus pulposus cell 
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by promoting expression of hypoxia-inducible factor to repair and reconstruct degenerated 
intervertebral disc [60].
In a recent study, under fluoroscopic guidance, the BMCs were injected into the nucleus pulp-
osus of 26 patients’ with chronic (>6 months) discogenic low back pain [61]. These authors 
found the evidence of safety and feasibility in the non-surgical treatment of discogenic pain 
using autologous BMCs with durable pain relief (71% VAS reduction) and Oswestry Disability 
Index improvements (>64%) through 2 years.
Overall, the BMSCs as a treatment of degenerated intervertebral disc is successful both in 
an animal model and in clinical studies; however, there are no long-term follow-up results 
and the number of reports and the number of cases are still relatively low. Another con-
cern is that, at least in theory, BMSCs may cause osteophyte formation in the vertebral isth-
mus when it is released from the nucleus. Further clinical trials are needed to clarify these 
concerns.
8. MSCs in osteoporosis
Osteoporosis is a common metabolic bone disease, characterized by loss of bone mass, 
bone density reduction, and bone structure damage, which leads to increased bone fragility 
and risks of bone fracture [62]. The exact underlying mechanisms of osteoporosis are still 
unclear, but a shift of the cell differentiation of MSCs to adipocytes rather than osteoblasts 
partly contributes to osteoporosis [63]. Furthermore, it was observed that osteoclast activ-
ity (bone resorption) was enhanced, while osteoblast function (bone formation) decreased. 
For this reason, the drugs that inhibit the activity of osteoclasts have been widely used in 
clinical practice; however, these drugs have many complications, such as mandibular necro-
sis, reflux esophagitis, and atypical fracture [62, 64]. Recently, it is found that the decrease 
of BMSC to osteogenic differentiation and the increase of lipid differentiation is an impor-
tant factor in the pathogenesis of osteoporosis [65, 66], therefore, one of the new ways to 
inhibit osteoporosis is to promote osteogenesis differentiation of endogenous BMSCs. In 
the meantime, BMSCs transplantation can also effectively increase bone mass and density, 
increase bone mechanical strength, correct the imbalance in bone metabolism, and increase 
bone formation, and is expected to provide a new strategy and method for the treatment of 
osteoporosis [67].
Scholars have carried out a large number of studies, including signal transduction, gene tran-
scription, and post-transcriptional level, and found that miRNA and epigenetic modifications 
are probably the main mechanisms for BMSC differentiation [63]. In addition, conserved sig-
nal regulation, mechanical stimuli, radiation, and diet also play important roles in regulating 
the differentiation fate of MSCs. Even though an MSC transplant could, at least in theory, 
provide a treatment for osteoporosis, the clinical trials of MSCs in osteoporosis have just 
begun; nevertheless, the animal studies have already found that autograft or allogeneic MSC 
transplantation can increase the bone mass of animal models of osteoporosis [66, 67]. Since 
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osteoporosis is a systemic disease, and the hormone levels and cytokines have changed dra-
matically, it is still unclear whether the simple local MSC transplantation can improve these 
changes in the long-term. In addition, the bone marrow homing efficiency of MSCs and the 
long-term survival of MSCs are still uncertain.
9. MSCs in genetic diseases
9.1. Osteogenesis imperfecta (OI)
Osteogenesis imperfecta is a rare congenital bone development disorder characterized by 
bone fragility, blue sclera, deafness, and joint relaxation. Horwitz et al. reported three cases of 
OI using allogeneic bone marrow cells [68]. Six months after the implantation, the new bone 
formation was observed with a reduced frequency of fractures, suggesting that bone marrow 
cells could be used to treat OI. The further study from the same group with BMSCs transplan-
tation [69], obtained similar results, that is, donor BMSCs survived in 5/6 OI patients’ which 
significantly improved the clinical symptoms of these patients.
9.2. Hypophosphatasia (HPP)
Hypophosphatasia is a rare, heritable, metabolic bone disease due to deficient activity of the 
tissue-nonspecific isoenzyme of alkaline phosphatase [70]. The disease is characterized by 
the disturbance of bone and tooth mineralization and reduced serum ALP activity. Tadokoro 
et al. used allogeneic MSCs obtained from the patient’s father for an 8-month-old patient with 
hypophosphatasia [71], and they observed improved respiratory condition, and de novo bone 
derived from both donor and patient cells. Similarly, Cahill et al. reported an 8-month-old girl 
with worsening and life-threatening infantile HPP improved considerably after marrow cell 
transplantation [72]. More importantly, 4 months after treatment, radiographs demonstrated 
improved skeletal mineralization. The authors speculated that donor bone fragments and 
marrow may provide precursor cells for distribution and engraftment in the skeletal micro-
environment in HPP patients to form tissue-nonspecific isoenzyme of alkaline phosphatase-
replete osteoblasts that can improve mineralization.
10. Conclusions
BMSCs are easy to obtain, isolated and amplified, which provide a wide application prospect 
for the treatment of orthopedic diseases. Here, we briefly reviewed the progressions ions of 
MSCs in a variety of orthopedic diseases. Many studies have demonstrated the safety and 
efficacy of autologous bone marrow MSCs transplantation in animal models as well as in 
human clinical trials. However, there are still some issues to be solved, such as the reference 
standards of BMSCs, the regulatory mechanism of proliferation and differentiation of BMSCs, 
the time, route of administration, and dosages of the transplant. With the further BMSCs 
researches, we believe that these problems will be solved soon.
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